

UNIVERSAL INFLUENZA VACCINES 2020

29-30 April – 1 May 2020, Richard Doll Building, University of Oxford, Oxford, UK

Progress towards a Universal Influenza Vaccine:
Potential Target Antigens and Critical Aspects for Vaccine Development

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR UIV 2020

Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness.

UIV 2020 – this new forum will offer researchers an opportunity to discuss the characteristics of universal influenza vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such universal influenza virus vaccines.

The UIV 2020 Scientific Advisory Panel are calling for abstracts for both oral and poster presentation at the meeting.

Abstracts should be sent directly to the UIV 2020 Secretariat (John Herriot at Meetings Management to email address: jherriot@meetingsmgmt.u-net.com).

SCIENTIFIC ADVISORY PANEL

UIV 2020 Conference Chairman:

Sarah Gilbert (*Jenner Institute, University of Oxford, Oxford, UK*)

Ted Ross (*University of Georgia, Athens, Georgia, USA*)

Sean Tucker (*VAXART Inc., South San Francisco, California, USA*)

John Oxford (*Queen Mary University of London, London, UK*)

Rob Lambkin-Williams (*hVIVO Ltd, London, UK*)

Christopher Chadwick (*World Health Organization, Geneva, Switzerland*)

Erin Sparrow (*World Health Organization, Geneva, Switzerland*)

Pamuk Bilsel (*FluGen Inc., Madison, Wisconsin, USA*)

Othmar Engelhardt (*NIBSC, South Mimms, Potters Bar, UK*)

Tobias Kamphuis (*Janssen Vaccines, Leiden, The Netherlands*)

Anke Huckriede (*University of Groningen, Groningen, The Netherlands*)

Ron Babecoff (*BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel*)

Tamar Ben-Yedidia (*BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel*)



Harry Kleantous (*Sanofi US, Cambridge, Massachusetts, USA*)

Baozhong Wang (*Georgia State University, Atlanta, Georgia, USA*)

Emanuele Montomoli (*VisMederi Srl, Siena, Italy*)

Otfried Kistner (*VisMederi, Siena, Italy*)

Joanna Waldoock (*NIBSC, South Mimms, Potters Bar, UK*)



Abstract Submissions

The UIV 2020 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during UIV 2020. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (UIV 2020 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 18th October 2019**. Authors will be informed of the status of their contribution(s) in November 2019. Closing date for submissions intended for poster presentation: **Friday 10th April 2020**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to UIV 2020. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at UIV 2020. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on UIV 2020
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of Abstract:

Intended Session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please type/print):

- My organisation is interested in sponsoring UIV 2020
- Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS** – 9-11 September 2019, Bern, Switzerland
- VACCINES FOR ENTERIC DISEASES** – 16-18 October 2019, Lausanne, Switzerland
- SKIN VACCINATION SUMMIT 2020** – 17-19 March 2020, Edinburgh, Scotland, UK
- VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES** – 15-17 June 2020, Riga, Latvia

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, UIV 2020, MEETINGS MANAGEMENT

Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom

Telephone: +44 (0)1483 427770 E-mail: jherriot@meetingsmgmt.u-net.com Website: www.meetingsmanagement.com/uiv_2020